NFE2L2 and chronic kidney disease: These dual pathogenic functions of NRF2 are further exemplified following clinical trials of the NRF2 activating CDDO-Me which, as discussed earlier, showed promise in the treatment of chronic kidney disease (CKD) during preclinical and phase II trials.